Axion BioSystems has developed the next generation multielectrode array (MEA) technology to provide unprecedented access to cellular information.

Axion Biosystems specializes in neural interfacing technologies with wide applicability to the research, clinical, and drug discovery markets. Our proprietary technology allows simultaneous stimulation and recording of neural tissue-an industry first-and includes low-power chips that service thousands of channels. While current development is focused on pharmaceutical drug screening, ongoing development will result in devices in the medical arena.